Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea
Authors:
- Adela R. CardonesACAdela R. Cardones
- Morgan E. BelinaMBMorgan E. Belina
- 11 April 2023
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , 390-392
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophagesAnnals of the Rheumatic Diseases, 2017
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsJournal of the American Academy of Dermatology, 2016
- Evaluation of the Efficacy and Safety of Topical Imiquimod 5% for Plaque-Type Morphea: A Multicenter, Prospective, Vehicle-Controlled TrialJournal of Cutaneous Medicine and Surgery, 2015
- Comparison of Outcomes in Adults With Pediatric‐Onset Morphea and Those With Adult‐Onset Morphea: A Cross‐Sectional Study From the Morphea in Adults and Children CohortArthritis & Rheumatology, 2014
- Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients With Skin DiseasesArchives of Dermatology, 1997